Siliq (brodalumab) / AstraZeneca, Bausch Health, LEO Pharma, Kyowa Kirin - LARVOL DELTA

Emerging Manifestations of IL-17 Immunomodulation in the Gastrointestinal Tract. (PubMed, Hum Pathol) - "Biologics targeting IL-17 (ixekizumab, secukinumab, brodalumab, bimekizumab) have been approved to treat conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The requirement of IBD biologics to achieve and maintain clinical/histologic remission in our cohort suggests that this process is more than a self-limited drug reaction. Future studies of expanded cohorts are required to determine whether IL-17 inhibitors unmask IBD in predisposed individuals or cause de novo IBD."

Journal • Ankylosing Spondylitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Primary Immunodeficiency • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Cost per Response Analysis of Deucravacitinib and Biologic Treatments for Moderate to Severe Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (ISPOR 2025) - "Deucravacitinib presented the lowest cost-per-response ratio amongst all treatments available for moderate to severe plaque psoriasis in the Brazilian private"

Dermatology • Immunology • Inflammation • Psoriasis

The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials. (PubMed, Autoimmun Rev) - "Secukinumab showed sustained hidradenitis Suppurativa Clinical Response (HiSCR) improvements, particularly in biologic-naïve patients with common adverse events (AEs). Bimekizumab was effective with biweekly dosing, while the four-week regimen had inconsistent results, with rare reports of AEs. Brodalumab and bermekimab provided rapid and sustained HiSCR responses with lesion reductions, which were well tolerated. Guselkumab and ustekinumab showed promising but statistically nonsignificant improvements with mild AEs. Risankizumab did not significantly improve HiSCR rates but showed Dermatology Life Quality Index (DLQI) benefits. Anakinra offered moderate efficacy with prolonged exacerbation-free periods but led to some treatment discontinuations. Spesolimab reduced inflammatory lesions and draining tunnels while maintaining a favorable safety profile. IL inhibitors, especially IL-17 inhibitors, have demonstrated efficacy in treating moderate-to-severe HS, while..."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IL17A • IL23A

Genetic polymorphisms in psoriasis: investigating genetic variations for precise profiling of response to brodalumab in real-life clinical practice. (PubMed, Actas Dermosifiliogr) - "This study identified genetic variations associated with the ability to achieve an optimal response to brodalumab, providing potential insights into its efficacy profile for treating plaque psoriasis."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • HTR2A

BRodalumab effectiveness in psoriatic patients that experienced anti-IL17 Intra-Class failure: a multicentre, retrospective study (BRIC - Study) IL-PSO (Italian Landscape Psoriasis). (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A

Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Treated with Biologics: A nationwide study using target trial emulation framework. (PubMed, Br J Dermatol) - "The findings suggested ustekinumab and guselkumab may be associated with a reduced risk of HZ and PHN, compared to TST. This study could have significance for real-world practice."

Journal • Dermatology • Herpes Zoster • Immunology • Inflammatory Arthritis • Neuralgia • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Varicella Zoster • IL12A • IL17A • IL23A

Summary of Research: Comparable Efficacy and Safety of Brodalumab in Obese and Nonobese Patients with Psoriasis: Analysis of Two Randomized Controlled Trials. (PubMed, Clin Drug Investig) - "Data were analyzed from two large, phase 3 clinical trials (AMAGINE-2 and AMAGINE-3) of participants with psoriasis who were treated with brodalumab or another subcutaneous injectable therapy, ustekinumab. Brodalumab safety profiles were generally similar between participants with and without obesity. This study demonstrated that brodalumab is effective and safe for treating moderate-to-severe psoriasis, regardless of obesity status."

Journal • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

Identifying transcriptomic predictors of brodalumab response in psoriasis using CART analysis. (PubMed, Arch Dermatol Res) - "The CART models demonstrated strong AUC values for the PASI75 (0.90) and PASI90 (0.88) analyses. Taken together, focused transcriptomics has the potential to be used clinically for the pre-treatment prediction of treatment response."

Journal • Dermatology • Immunology • Psoriasis • FERMT1 • HLA-DQA1 • HTRA1 • KRT16 • S100P

Real-world experience with brodalumab in a Portuguese cohort of patients with moderate-to-severe psoriasis. (PubMed, Drugs Context) - "The occurrence of adverse events was low and restricted to non-severe infectious. This real-world data show that brodalumab is effective and safe for the treatment of moderate-to- severe psoriasis."

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A • IL17RA

Brodalumab for Darier Disease: A Case Series Highlighting IL-17 Inhibition as a Potential Treatment. (PubMed, Int J Dermatol) - No abstract available

Journal • IL17A

Brodalumab for the treatment of palmoplantar psoriasis. (PubMed, Ital J Dermatol Venerol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years. (PubMed, Dermatol Ther (Heidelb)) - "This study provides valuable insights into the profile of patients treated with brodalumab in Canada. While the rapid and sustained skin clearance, as well as improvements in PASI, BSA, and DLQI scores, support the therapeutic benefits of brodalumab beyond clinical trials, further research on long-term effectiveness and safety is warranted."

Journal • Real-world evidence • Retrospective data • Dermatology • Immunology • Inflammation • Psoriasis

Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review. (PubMed, Acta Derm Venereol) - "The included studies reported a total of 837 cases: 179 patients were treated with secukinumab, 69 with ixekizumab, 8 with brodalumab, 539 with risankizumab, 22 with guselkumab, and 20 with tildrakizumab. Our analysis shows that IL-17 and IL-23 inhibitors do not increase the risk of tuberculosis activation in psoriatic patients with latent tuberculosis infection. The impact of IL-12/23 inhibitors on tuberculosis reactivation among psoriatic patients with latent tuberculosis infection remains uncertain and requires further investigation."

Journal • Review • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IL12A • IL17A • IL23A

Do patients with psoriasis and psoriatic arthritis receive adequate therapy for both? - Data from the German national psoriasis registry PsoBest (AAD 2025) - "PSO patients most commonly received adalimumab (37.2%), fumaric acid esters (31.5%) and methotrexate (18.9%), while PsA patients were prescribed adalimumab (27.1%), methotrexate (21.6%) and secukinumab (13.6%), with biologics significantly more frequently used in PsA (p<0.05). Remarkably, unapproved systemic medications for PsA, such as fumarate esters or cyclosporine, which have no evidence of benefit in this condition, were found in 5.7% and 1.2% of PsA patients. Brodalumab as IL17-inihibitor does not have approval for PsA in Europe, though other IL17 inhibitors are approved for PsA, but was found in 1.8%... Early and effective treatment of PsA is crucial to prevent damage of the joints. In total, 8.8% of patients with PsA were not treated in compliance with guidelines. To manage the entire systemic inflammation we need to choose guideline-conform medication and interdisciplinary collaboration should be emphasised."

Clinical • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Failure of IL-17 and IL-23 Inhibitors: Real-World Experience of Biologic Switching in Psoriasis (AAD 2025) - " Patients using IL-17 (secukinumab, ixekizumab, brodalumab) and IL-23 (guselkumab) inhibitors and subsequently switching to those mentioned biologics were retrospectively reviewed. Switching intra- or interclass between IL-17 and IL-23 inhibitors showed variable effectiveness. Identifying factors associated with switching may optimize psoriasis treatment."

Clinical • Real-world • Real-world evidence • Dermatology • Diabetes • Immunology • Metabolic Disorders • Psoriasis • IL17A • IL23A

Efficacy of brodalumab in obese patients with psoriasis: case series in real clinical practice (AAD 2025) - "These results show no differences in PASI100 response achieved between obese and nonobese patients, both in short and long term. Brodalumab is an interesting alternative in treatment of obese patients with psoriasis for whom achieving an optimal response is a therapeutic challenge."

Clinical • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis

Efficacy and Safety of IL-17 and JAK Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis. (PubMed, Int Arch Allergy Immunol) - "The results of the network meta-analysis showed that netakimab 120mg ranked relatively high in outcome of ASAS20 and ASAS40. All treatments with IL-17 and JAK inhibitors were generally safe and well tolerated. However, the two included netakimab clinical studies may have limitations. Therefore, the therapeutic agents should be carefully selected in clinical treatment. Moreover, the efficacy and safety of netakimab remain to be further analyzed in studies with larger sample sizes and longer follow-up times."

Journal • Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Assessing brodalumab in the treatment of primary sclerosing cholangitis (SABR-PSC pilot study): protocol for a single-arm, multicentre, pilot study. (PubMed, BMJ Open Gastroenterol) - "A summary of the findings will also be shared with participants and PSC communities. ISRCTN15271834."

Clinical protocol • Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • IL17A

Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study. (PubMed, Dermatol Ther (Heidelb)) - "Our study confirmed the efficacy and safety of both bimekizumab and brodalumab, up to 36 weeks of treatment. Although both drugs showed a significant improvement of the investigated scores from week 4, some differences in terms of PASI90 and PASI100 responses (higher for bimekizumab at each follow-up, with only PASI100 response significantly higher at week 4 and 16) were registered. No statistical significance was found for safety data and treatment failure."

Journal • Atopic Dermatitis • Candidiasis • Dermatology • Immunology • Psoriasis • IL17A • IL17RA

Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis). (PubMed, J Clin Med) - "The probability of achieving PASI 75 and PASI 100 was independent of nutritional status at any time during the study. In conclusion, our results confirm that brodalumab has both rapid and sustained effectiveness in patients with moderate-to-severe psoriasis; our results could be extended to patients with multiple risk factors impairing treatment response, such as multiple biological failure and obesity."

Clinical • Journal • Real-world evidence • Retrospective data • Dermatology • Genetic Disorders • Immunology • Obesity • Psoriasis • IL17A • IL17RA

A case of systemic sclerosis accompanying psoriasis successfully treated with brodalumab. (PubMed, J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis • Scleroderma • Systemic Sclerosis

PSO-TARGET: a New Tool to Identify the Therapeutic Expectations of Psoriasis Patients Treated with Biologics. (PubMed, Dermatol Ther (Heidelb)) - P | "This study highlights the importance of considering patient characteristics of those with psoriasis and perspectives when evaluating treatment outcomes. Using shared decision-making tools such as the PSO-TARGET grid can improve communication and understanding between dermatologists and patients."

Journal • Dermatology • Immunology • Psoriasis

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience. (PubMed, Dermatol Reports) - "Among these, ixekizumab, secukinumab, brodalumab, and bimekizumab are approved for the treatment of moderate-to-severe plaque psoriasis. Our study confirms the safety and effectiveness of intraclass switching among IL-17 antagonists, highlighting that an inter-class switch can be a valid option when patients fail to respond or lose effectiveness with an IL-17 inhibitor. However, further larger and longer studies are needed for a deeper understanding."

Journal • Cardiovascular • Dermatology • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders • Psoriasis • Pulmonary Arterial Hypertension • IL17A • IL23A • TNFA

Lichenoid drug eruption during treatment with brodalumab for psoriasis. (PubMed, Ital J Dermatol Venerol) - No abstract available

Journal • Dermatology • Immunology • Lichen Planus • Psoriasis

Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis). (PubMed, J Dermatolog Treat) - No abstract available

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis